Locally ablatIVe thErapy for oLigo-progressive gastrOintestiNal maliGnancies (LIVELONG)

This study — called LIVELONG — is testing whether using targeted local treatments (such as radiation or ablation) to destroy a small number of newly growing or progressing tumor sites can help people with gastrointestinal cancers stay on their current systemic treatment longer. It targets patients whose cancer is mostly stable on treatment except for a few new or growing spots. **You may be eligible if...** - You are 18 years or older - You have a confirmed gastrointestinal cancer (esophageal, gastric, colorectal, biliary, liver, pancreatic, or small bowel) - You are currently on systemic therapy (e.g., chemotherapy, targeted therapy) that is mostly working - You have had at least one prior treatment line with at least 3 months of benefit - You have 5 or fewer new or progressing cancer spots that can be treated with local ablative therapy - Your treating doctors agree all progressing spots can be safely targeted **You may NOT be eligible if...** - You have medical conditions preventing safe use of ablative therapies - Your progressing lesions are in the brain (intracranial) - Your overall tumor burden is broadly progressing (not just a few spots) Talk to your doctor to see if this trial is right for you.